Boston Scientific Corporation

Boston Scientific Corporation is an American multinational biotechnology and biomedical engineering firm that develops, manufactures, and markets medical devices. Headquartered in Marlborough, Massachusetts, the company's mission is to transform lives through innovative medical solutions that improve the health of patients around the world.

The company operates primarily through two reportable segments: Cardiovascular and MedSurg. Its extensive product portfolio addresses various interventional medical specialties, including interventional cardiology, peripheral interventions, electrophysiology, neuromodulation, endoscopy, oncology, urology, and gynecology. Key products include the WATCHMAN FLX Left Atrial Appendage Closure Device, the FARAPULSE™ Pulsed Field Ablation (PFA) System, implantable cardioverter-defibrillators, pacemakers, and a wide range of catheters and stents.

Led by Chairman and CEO Michael F. Mahoney, Boston Scientific reported net sales of $5.203 billion in the first quarter of 2026, reflecting significant growth. The company maintains a strong market position in the medical device industry, focusing on less-invasive medical technologies and expanding its global presence, particularly in emerging markets. Recent strategic acquisitions, such as Axonics and Silk Road Medical, have further bolstered its offerings in areas like urology and stroke prevention. However, the company recently addressed a Class I recall related to certain pacemakers, providing a software update to mitigate safety concerns.